FDA-approved dose of salsalate improves glucose and lipid metabolism in type 2 diabetes

被引：0
|
作者：
Silver, RJ
Aldhahi, W
Shoelson, SE
Goldfine, AB
机构：
来源：
DIABETES | 2004年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A161 / A161
页数：1
相关论文
共 50 条
  • [1] Novel FDA-approved bexagliflozin drug for treating type 2 diabetes mellitus
    Saleem, Muhammad M.
    Zubair, Muhammad S.
    Abbas, Soha
    Hojeij, Moussa
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (11): : 6399 - 6403
  • [2] Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes
    Mahajan, Rajiv
    INDIAN JOURNAL OF PHARMACOLOGY, 2009, 41 (04) : 197 - 198
  • [3] Leucine improves brain glucose and lipid metabolism in type 2 diabetes
    Erukainure, O. L.
    Olofinsan, K.
    Salau, V.
    Islam, M. S.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [4] Lantidra, First FDA-Approved Cellular Therapy to Treat Type 1 Diabetes
    Rios, Peter
    McGarrigle, James J.
    Lamonica, Giovanna
    Li, Yi
    Cook, Jennifer
    Joshi, Ira
    Ghani, Sofia
    Cook, David
    Lopez, Daisy
    Nasir, Hafsa
    Wang, Yong
    Oberholzer, Jose
    DIABETES, 2024, 73
  • [5] Minority Inclusion in 2014 FDA-Approved Type 2 Diabetic Drugs
    Merenda, Christine
    Marwitz, Kathryn
    DIABETES, 2016, 65 : A301 - A301
  • [6] Photoelectric Dose-Enhancement Using FDA-Approved Materials
    Swanson, W.
    Hao, Y.
    Ngwa, W.
    MEDICAL PHYSICS, 2021, 48 (06)
  • [7] Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes
    Hundal, RS
    Petersen, KF
    Mayerson, AB
    Randhawa, PS
    Inzucchi, S
    Shoelson, SE
    Shulman, GI
    JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (10): : 1321 - 1326
  • [8] Absorption, Distribution, Metabolism, and Excretion of FDA-approved Antisense Oligonucleotide Drugs
    Migliorati, Julia M.
    Liu, Sunna
    Liu, Anna
    Gogate, Anagha
    Nair, Sreenidhi
    Bahal, Raman
    Rasmussen, Theodore P.
    Manautou, Jose E.
    Zhong, Xiao-bo
    FASEB JOURNAL, 2022, 36
  • [9] Tesaglitazar improves glucose and lipid abnormalities in patients with type 2 diabetes
    Goldstein, BJ
    Rosenstock, J
    Anzalone, D
    Tou, C
    Öhman, P
    DIABETES, 2005, 54 : A21 - A21
  • [10] Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2
    Detroja, Trishna Saha
    Samson, Abraham O.
    MOLECULES, 2022, 27 (16):
12345